Media
Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
April 27, 2020, Shanghai
Hua Medicine (the"Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112.
HMM0112 is a Phase I trial conducted in the United States in Type 2 Diabetes (T2D) patients with insufficiently controlled blood glucose levels while on metformin, DPP-4 inhibitors or SGLT-2 inhibitors, alone or in combination treatment. The principal purpose of HMM0112 is to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of dorzagliatin and empagliflozin (a SGLT-2 inhibitor) as either monotherapy or combination therapy. The PK results demonstrated no impact of dorzagliatin (75 mg BID) and empagliflozin (25 mg QD) on their respective PK properties under co-administration, supporting their combination use in the clinical setting, while the PD results demonstrated a clear synergistic effect in efficacy under combination therapy. Following OGTT, the combination treatment achieved significantly enhanced glucose lowering effect (AUEC: 279 h•mg/dL) over empagliflozin (AUEC: 452 h•mg/dL, P<0.01) or dorzagliatin (AUEC: 364 h•mg/dL, P<0.05) monotherapy. Moreover, significantly increased C-peptide secretion was also observed for the combination treatment over empagliflozin monotherapy. These results support the development of a combination therapy of dorzagliatin with empagliflozin, which will provide improved benefits and better solutions to T2D patients.
“SGLT-2 inhibitors are a relatively newer class of oral medications for the treatment of T2D patients, in addition to the blood sugar control, they were found to have the effect to lower blood pressure and reduce body weight. Their global sales in 2019 were approximately 6 billion US dollars,” said Dr. Li Chen, Chief Executive Officer of Hua Medicine, “The positive results of HMM0112 indicate that dorzagliatin add-on to SGLT-2 inhibitors enhanced the blood sugar control for T2D patients thereby expanding the applicable patient population, and also suggest a synergistic effect of recovering pancreatic islet function. This successful outcome advances our mission to offer dorzagliatin as either monotherapy or in combination with the currently approved top-selling oral anti-diabetic drugs. Currently, we have demonstrated similar positive results of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor and top-selling oral anti-diabetic drug in the world) and metformin (the global first-line oral anti-diabetic drug). In this fashion, we are aiming to provide a brand new treatment for T2D patients to prevent or delay occurrence of the diabetes and its complications through dorzagliatin monotherapy or in combination with currently available diabetes therapies.”
In November 2019, Hua Medicine announced that the Phase III monotherapy trial (HMM0301) of dorzagliatin in drug naïve T2D patients achieved its 24-week primary efficacy endpoint. The Company plans to announce the top-line 52-week key results for the monotherapy trial by no later than the third quarter of 2020. The 24-week patient visit for HMM0302, another Phase III combination trial of dorzagliatin add-on to metformin, was also completed. The Company plans to announce the top-line 24-week key results for the combination with metformin trial (HMM0302) by no later than the third quarter of 2020, and top-line 52-week key results by year-end 2020. In January 2020, the Company also announced the desirable results of dorzagliatin combination with sitagliptin Phase I trial (HMM0111), confirming the clinical advantages and potential synergies of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor). Meanwhile, the positive results of another Phase I trial (HMM0110) revealed the potential to use dorzagliatin in T2D patients with late stage chronic kidney disease.
About Dorzagliatin
Dorzagliatin is a first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in people with type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of people with type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and in two Phase I trials in the United States. The company has also initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Hua Medicine
Website: kpgagr.yunxiabc.com
Investors
Email: ir@yunxiabc.com
Media
Email: pr@yunxiabc.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
